Page 55 - Read Online

Loong et al. J Transl Genet Genom 2023;7:27-49 https://dx.doi.org/10.20517/jtgg.2022.20 Page 49

19. Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ
Res 2017;121:749-70. DOI PubMed PMC
20. Ingles J, Goldstein J, Thaxton C, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis
Med 2019;12:e002460. DOI PubMed PMC
21. Konno T, Chang S, Seidman JG, Seidman CE. Genetics of hypertrophic cardiomyopathy. Curr Opin Cardiol 2010;25:205-9. DOI
PubMed PMC
22. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic
cardiomyopathy. N Engl J Med 1995;332:1058-64. DOI
23. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial
hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248-57. DOI PubMed
24. Ko C, Arscott P, Concannon M, et al. Genetic testing impacts the utility of prospective familial screening in hypertrophic
cardiomyopathy through identification of a nonfamilial subgroup. Genet Med 2018;20:69-75. DOI PubMed
25. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med
2005;352:362-72. DOI PubMed
26. Maron BJ, Desai MY, Nishimura RA, et al. Management of Hypertrophic Cardiomyopathy: JACC state-of-the-art review. J Am Coll
Cardiol 2022;79:390-414. DOI PubMed
27. Maron BJ, Rowin EJ, Maron MS. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy:
twenty years with the implantable cardioverter-defibrillator. Heart Rhythm 2021;18:1012-23. DOI PubMed
28. Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers 2019;5:32. DOI
29. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American heart
association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care
and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on
epidemiology and prevention. Circulation 2006;113:1807-16. DOI PubMed
30. Nugent AW, Daubeney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med
2003;348:1639-46. DOI PubMed
31. Towbin JA, Lowe AM, Colan SD, et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA
2006;296:1867-76. DOI PubMed
32. Pinto YM, Elliott PM, Arbustini E, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated
cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and
pericardial diseases. Eur Heart J 2016;37:1850-8. DOI PubMed
33. Morales A, Hershberger RE. Genetic evaluation of dilated cardiomyopathy. Curr Cardiol Rep 2013;15:375. DOI PubMed
34. van Spaendonck-Zwarts KY, van Rijsingen IA, van den Berg MP, et al. Genetic analysis in 418 index patients with idiopathic dilated
cardiomyopathy: overview of 10 years’ experience. Eur J Heart Fail 2013;15:628-36. DOI PubMed
35. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the
channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and
the European Heart Rhythm Association (EHRA). Heart Rhythm 2011;8:1308-39. DOI
36. Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J 2015;36:1123-35a. DOI
PubMed
37. Escobar-Lopez L, Ochoa JP, Mirelis JG, et al. Association of genetic variants with outcomes in patients with nonischemic dilated
cardiomyopathy. J Am Coll Cardiol 2021;78:1682-99. DOI PubMed
38. Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol
2019;74:1480-90. DOI PubMed PMC
39. van den Hoogenhof MMG, Beqqali A, Amin AS, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy related
to disturbed calcium handling. Circulation 2018;138:1330-42. DOI PubMed
40. Kayvanpour E, Sedaghat-Hamedani F, Amr A, et al. Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on
more than 8000 individuals. Clin Res Cardiol 2017;106:127-39. DOI PubMed
41. Hasselberg NE, Haland TF, Saberniak J, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart
transplantation. Eur Heart J 2018;39:853-60. DOI PubMed PMC
42. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC mutations are associated with high-risk dilated and arrhythmogenic
cardiomyopathies. J Am Coll Cardiol 2016;68:2440-51. DOI PubMed
43. Helms AS, Thompson AD, Day SM. Translation of new and emerging therapies for genetic cardiomyopathies. JACC Basic Transl Sci
2022;7:70-83. DOI PubMed PMC
44. Verdonschot JAJ, Hazebroek MR, Ware JS, Prasad SK, Heymans SRB. Role of targeted therapy in dilated cardiomyopathy: the
challenging road toward a personalized approach. J Am Heart Assoc 2019;8:e012514. DOI PubMed PMC
45. Bosman LP, Sammani A, James CA, et al. Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a
systematic review and meta-analysis. Heart Rhythm 2018;15:1097-107. DOI PubMed
46. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed
modification of the Task Force Criteria. Eur Heart J 2010;31:806-14. DOI
47. van Lint FHM, Murray B, Tichnell C, et al. Arrhythmogenic right ventricular cardiomyopathy-associated desmosomal variants are